ID

34335

Description

Combination Treatment for Advanced Liver Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02149771

Link

https://clinicaltrials.gov/show/NCT02149771

Keywords

  1. 1/16/19 1/16/19 -
  2. 4/26/20 4/26/20 -
  3. 5/1/20 5/1/20 -
  4. 9/20/21 9/20/21 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 16, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatocellular Carcinoma NCT02149771

Eligibility Hepatocellular Carcinoma NCT02149771

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
Description

ID.1

Data type

boolean

(2) child-pugh classification grade a or b;
Description

ID.2

Data type

boolean

(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
Description

ID.3

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
Description

ID.4

Data type

boolean

tumor invade the inferior vena cava, extrahepatic spread;
Description

ID.5

Data type

boolean

contraindications for doxorubicin or oxaliplatin chemotherapy;
Description

ID.6

Data type

boolean

any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
Description

ID.7

Data type

boolean

renal failure,cardiac ejection fraction <50 %) or end-stage disease;
Description

ID.8

Data type

boolean

patients who were not capable of cooperation during the procedure.
Description

ID.9

Data type

boolean

Similar models

Eligibility Hepatocellular Carcinoma NCT02149771

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
boolean
ID.2
Item
(2) child-pugh classification grade a or b;
boolean
ID.3
Item
(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
boolean
ID.5
Item
tumor invade the inferior vena cava, extrahepatic spread;
boolean
ID.6
Item
contraindications for doxorubicin or oxaliplatin chemotherapy;
boolean
ID.7
Item
any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
boolean
ID.8
Item
renal failure,cardiac ejection fraction <50 %) or end-stage disease;
boolean
ID.9
Item
patients who were not capable of cooperation during the procedure.
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial